Two cases of patients with Parkinson's disease developing valvular heart disease while taking cabergoline

• Published in: Rinsho Shinkeigaku Vol. 48; no. 7; pp. 486 - 491
• Main Authors: Sato, Takashi, Kikuchi, Akio, Onoue, Noriko, Hiramoto, Tetuya, Oumi, Mikio, Onodera, Junichi
• Format: Journal Article
• Language: Japanese
• Published: Japan Societas Neurologica Japonica 01.07.2008
• Subjects: Aged; Antiparkinson Agents - adverse effects; cabergoline; cardiac valvulopathy; dopamine agonist; echocardiography; Ergolines - adverse effects; Fatal Outcome; Female; Heart Failure - chemically induced; Heart Valve Diseases - chemically induced; Humans; Parkinson Disease - drug therapy; Parkinson's disease

We experienced 2 patients of valvular heart disease in Parkinson's patients taking cabergoline. Patient 1 was a 79-year-old woman who began taking 4 mg cabergoline daily after being diagnosed with Parkinson's disease (PD) in June 2003. She presented with dyspnea in November 2005. The patie...